Background: The optimal hemoglobin (Hb) range in patients undergoing hemodialysis remains controversial. We aimed to investigate the association between Hb levels and mortality in patients undergoing hemodialysis and explore the potential factors modifying this association. Methods: This observational study utilized a nationwide database from the Japanese Renal Data Registry spanning from 2019 to 2021. This study included 265,779 patients undergoing hemodialysis thrice a week. The association between Hb levels and all-cause and cause-specific mortality was investigated using Cox regression analysis. The nonlinear relationship between Hb levels and outcomes was investigated using restricted cubic spline analysis. Results: During a median follow-up period of 24 months, 45,734 patients died. Compared to the reference Hb category of 10–10.9 g/dL, the risk of all-cause mortality was higher in the Hb categories of < 9.0, 9.0–9.9, and ≥ 13 g/dL with adjusted hazard ratios (95% confidence intervals) of 1.24 (1.20–1.29), 1.09 (1.06–1.12), and 1.19 (1.14–1.25), respectively. Restricted cubic spline analysis also showed a U-shaped relationship between Hb level and mortality. The subgroup analysis indicated that the Hb category of 12.0–12.9 g/dL was associated with increased mortality risk in patients with a dialysis vintage of ≥ 10 years and those with a history of cerebral infarction. Conclusion: Hb levels of < 10.0 and ≥ 13.0 g/dL were significantly associated with an increased mortality risk compared to an Hb level of 10.0–10.9 g/dL in patients undergoing hemodialysis.
2 November 2024 in Journal of the American Geriatrics Society
Key Points: Systematic review/meta-analysis of 23 studies (15,289 patients) quantified prognostic effect of low-grade proteinuria in IgA nephropathy. Low-grade proteinuria (0.5–1.0 g/d) linked to higher kidney risk (hazard ratio, 1.73–2.87) and faster eGFR decline (−1.02 ml/min per year). Long-term suppression below 0.5 g/d should be a key therapeutic goal, supporting current IgA nephropathy clinical guidelines. Background: Overt proteinuria (>1.0 g/d) is a well-established risk factor for kidney disease progression in IgA nephropathy. However, recent evidence suggests that even low-grade proteinuria, typically defined as 0.5–1.0 g/d, may be clinically significant. The prognostic effect of low-grade proteinuria has not been systematically evaluated. Methods: We conducted a systematic review and meta-analysis to evaluate the association between low-grade proteinuria and adverse kidney outcomes in patients with IgA nephropathy. A systematic literature search was performed on PubMed and Web of Science. Eligible studies included those reporting on kidney outcomes such as eGFR decline, kidney failure, or eGFR slope in relation to low-grade proteinuria measured either at baseline or during follow-up ( e.g ., time-averaged proteinuria). Data were synthesized using random-effects meta-analysis. The protocol was registered in the Open Science Framework REGISTRIES (https://osf.io/5dfqr). Results: A total of 23 studies ( N =15,289) met the inclusion criteria, of which 15 contributed to at least one meta-analysis. Baseline low-grade proteinuria was significantly associated with an increased risk of adverse kidney outcomes compared with proteinuria below 0.5 g/d (pooled hazard ratio, 1.73; 95% confidence interval [CI], 1.36 to 2.20; nine studies). Similarly, low-grade time-averaged proteinuria was associated with a higher risk of kidney outcomes (pooled hazard ratio, 2.87; 95% CI, 1.48 to 5.56; seven studies) and a significantly steeper annual decline in eGFR (mean difference, −1.02 ml/min per 1.73 m 2 per year; 95% CI, −1.60 to −0.45; four studies). Subgroup analyses and leave-one-out sensitivity analyses were consistent with the overall findings. Conclusions: Low-grade proteinuria, whether assessed at baseline or over time, is an important predictor of kidney disease progression in patients with IgA nephropathy. These results reinforce recent clinical guidelines recommending proteinuria control under 0.5 g/d. Long-term suppression of proteinuria should be considered a key therapeutic goal in IgA nephropathy.
Anemia is a common complication associated with adverse outcomes in older patients undergoing hemodialysis (HD). They also tend to experience malnutrition, which can affect the course of anemia. We hypothesized that the optimal hemoglobin (Hb) level varies depending on nutritional status in older patients undergoing HD and aimed to investigate the association between Hb levels and mortality according to nutritional status. This is an observational study utilizing a nationwide Japanese database from 2019 to 2021. This study included 95,771 patients aged ≥75 years undergoing HD thrice a week. The nutritional risk index for Japanese hemodialysis patients (NRI-JH) was calculated. The association between Hb levels and mortality was investigated using Cox regression analysis stratified by NRI-JH. A nonlinear relationship was investigated using restricted cubic spline analysis. During a median follow-up period of 24 months, 27,611 patients died. In the low-risk NRI-JH group, the risk of all-cause mortality was higher in the Hb categories of <9.0, 9.0-9.9, and ≥13 g/dL compared to the reference Hb category of 10-10.9 g/dL, with the adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) of 1.45 (1.32-1.59), 1.15 (1.08-1.22), and 1.18 (1.07-1.29), respectively. In contrast, the impact of Hb levels on mortality was significantly attenuated in the high-risk NRI-JH group, with a mild increased risk in the <9.0 g/dL category (aHR, 1.07; 95% CI, 1.01-1.15). Among older patients undergoing HD, the impact of Hb levels on mortality was attenuated in the high-risk NRI-JH group.
Key Points: Sodium-glucose cotransporter 2 inhibitors (SGLT2is) significantly slowed chronic decline in eGFR in nondiabetic CKD patients without proteinuria. Propensity score–matched analysis confirmed that SGLT2i users had a significantly slower postinitial dip eGFR slope than nonusers. Subgroup analyses consistently supported the renoprotective effect of SGLT2is in this population. Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2is) have shown promise as renoprotective agents, building on the success of renin-angiotensin system blockers. Although SGLT2is have been shown to slow renal deterioration in diabetic and nondiabetic CKD with proteinuria, it is unclear whether similar effects occur in nondiabetic, nonproteinuric CKD. Methods: This study used propensity score analysis to evaluate the effects of SGLT2is on changes in annual eGFR in nondiabetic CKD patients with trivial proteinuria (urinary protein–creatinine ratio <0.5 g/gCr) who were seen at the Nara Prefecture General Medical Center from January 1, 2019, to December 31, 2022. The study analyzed 362 nondiabetic patients with CKD, including 211 SGLT2i users and 151 nonusers, with a median age of 65 (53–73) years, median eGFR of 45 (35–53) ml/min per 1.73 m 2 , and median urinary protein–creatinine ratio of 0.15 (0.09–0.29) g/gCr. Results: Adjusted linear mixed-effects models showed that while the eGFR decline over a 3-year period (total) was similar between the two groups, there was a significantly smaller decline between 3 months after baseline and 2-year follow-up (chronic) in SGLT2i users compared with nonusers, with a difference of 1.23 (95% confidence interval, 0.43 to 2.02; P = 0.002) ml/min per 1.73 m 2 per year. After propensity score matching, SGLT2i users exhibited significantly slower chronic decline than nonusers, with a difference of 1.50 (95% confidence interval, 0.63 to 2.36; P < 0.001) ml/min per 1.73 m 2 per year. Subgroup analyses confirmed these findings. Conclusions: This study suggests that SGLT2is may slow eGFR decline in non-diabetic CKD patients with trivial proteinuria, supporting the potential use of SGLT2is as renoprotective agents in this population.
Sodium-glucose cotransporter 2 inhibitors (SGLT2is) are novel renoprotective agents for patients with chronic kidney disease (CKD) and have diverse effects, including on the regulation of electrolyte balance. However, their effects on serum chloride concentrations remain unclear. We conducted a retrospective single-center study of 343 CKD patients without diabetes or proteinuria who were not taking diuretics, including 202 SGLT2i users and 141 non-users, and applied propensity score (PS) matching and LASSO regression analysis. The outcomes were the change in chloride concentration with adjustment for covariates, before and after PS matching. Factors associated with these changes were identified using multivariable analysis and LASSO regression. An adjusted linear mixed effects model showed that the annual changes in chloride concentration for the non-SGLT2i and SGLT2i users were -0.39 (95% CI: -0.61 to 0.17) mEq/L/year and 0.49 (95% CI: -0.02 to 1.00) mEq/L/year, respectively [difference 0.88 (95% CI: 0.58 to 1.17) mEq/L/year] (p < 0.001). After PS matching, there was also a significant difference between users and non-users of SGLT2is in the mean change in chloride concentration [difference 0.44 (95% CI: 0.03 to 0.84) mEq/L/year] (p = 0.036). Subgroup analyses confirmed these findings. Furthermore, the use of SGLT2is had the strongest influence on the 2-year change in serum chloride concentration. To our knowledge, this is the first propensity-matched study to demonstrate a sustained chloride-preserving effect of SGLT2 inhibitors in non-diabetic CKD. In conclusion, this study identifies a previously underrecognized tubular electrolyte effect of SGLT2 inhibitors-preservation of serum chloride-which may partly explain their consistent cardioprotective effects across diverse CKD populations.